The study also found LAC is the most powerful predictor of pregnancy outcome; 44% of pregnancies in women with APS and LAC resulted in adverse pregnancy outcomes despite treatment with heparin and low-dose aspirin.
In recognition that pregnant women with APS have a pronounced unmet medical need, Dr. Branch and colleagues have initiated the Improve Pregnancy in APS with Certolizumab Therapy (IMPACT) study. The investigators want to determine whether tumor necrosis factor-α blockade (certolizumab) during pregnancy, added to a regimen of heparin and low-dose aspirin, reduces the rate of adverse pregnancy outcomes in women with clinical APS and LAC, and alters angiogenic markers of poor placental vascularization. Dr. Branch encouraged the audience to inform their patients about the trial, which is actively recruiting patients from around the country.
Limited Disease Awareness
Doruk Erkan, MD, MPH, attending physician at the Hospital for Special Surgery, New York, and associate professor of medicine at Weill Cornell Medicine, New York, explained one of the biggest problems associated with APS is limited disease awareness. This causes patient frustration, missed diagnosis and overdiagnosis. He said APS is one of the few conditions in which both under and overdiagnosis are problems.